Company Overview of Neurim Pharmaceuticals (1991) Ltd.
Neurim Pharmaceuticals (1991) Ltd. operates as a drug discovery and development company. It focuses on age-related disorders in the central nervous system. The company provides Circadin, a prolonged release melatonin for insomnia. Its products include orlogin, for circadian rhythm disorders; Neu-120, which has been developed as adjunct therapy to levodopa in patients with motor fluctuations; Neu-P11, a melatonin agonist binds with high affinity to melatonin receptors; and Neu-105 for the treatment of asthma. The company was founded in 1991 and is based in Tel-Aviv, Israel.
8 Hanechoshet St.
Founded in 1991
Key Executives for Neurim Pharmaceuticals (1991) Ltd.
Founder and Chief Scientific Officer
Chief Operating Officer and Chief Financial Officer
Head of Investor Relations
Compensation as of Fiscal Year 2014.
Neurim Pharmaceuticals (1991) Ltd. Key Developments
Neurim Pharmaceuticals (1991) Ltd. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014
Sep 10 14
Neurim Pharmaceuticals (1991) Ltd. Presents at EBD Group's Biopharm America 2014 Conference, Sep-22-2014 . Venue: Boston Marriott Copley Place, 110 Huntington Avenue, Boston, MA 02116, United States.
Neurim Pharmaceuticals Announces Publication of Positive Effects of Add-on Circadin® in Alzheimer's Disease Patients
Jun 19 14
Neurim Pharmaceuticals announced publication of the results from an exploratory Phase 2 randomized placebo-controlled clinical trial evaluating the safety and efficacy of add-on Circadin(R) (Prolonged Release melatonin 2mg) to standard therapy in Alzheimer's disease (AD) patients. The study, published in the Clinical Interventions in Aging Journal, demonstrates positive effects of the drug on cognitive performance and sleep maintenance in the AD patients. In this study, 80 patients diagnosed with mild-to-moderate Alzheimer's disease, with and without insomnia co-morbidity, receiving standard therapy (acetylcholinesterase inhibitors with or without memantine) were randomly assigned in a double-blind manner to 2 mg of Circadin(R) or placebo treatment nightly for 24-weeks. The paper reports that patients treated with Circadin(R) for 6 months had significantly better cognitive performance than those with placebo as measured by Instrumental Activities of Daily Living (IADL) and Mini Mental State Examination (MMSE). Mean Alzheimer's Disease Assessment Scale - cognition (ADAS-Cog) did not differ between groups. Sleep efficiency as measured by Pittsburgh Sleep Quality Index (PSQI) Component 4 also improved with Circadin(R). In a subgroup of patients suffering from comorbid insomnia, Circadin(R) treatment resulted in significant and clinically meaningful effects vs. placebo in mean IADL (p=0.032), MMSE (+1.5 vs. -3 points, p=0.0177) sleep efficiency (p=0.04), and median ADAS-Cog values (-3.5 vs. +3 points, p=0.045). The treatment was well tolerated.
Neurim Pharmaceuticals (1991) Ltd. Presents at ChinaBio(R) Partnering Forum 2014, May-08-2014 02:15 PM
May 1 14
Neurim Pharmaceuticals (1991) Ltd. Presents at ChinaBio(R) Partnering Forum 2014, May-08-2014 02:15 PM. Venue: Kempinski Hotel Suzhou, Suzhou, China.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|